argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026

Company Overview - argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [3] - The company is known for developing and commercializing the first approved neonatal Fc receptor (FcRn) blocker, with ongoing evaluations of its potential in various serious autoimmune diseases [3] Upcoming Events - argenx will host a conference call and audio webcast on February 26, 2026, at 2:30 PM CET (8:30 AM ET) to discuss its full year 2025 financial results and provide a fourth quarter business update [1] - The live call can be accessed via the Investors section of the argenx website, with a replay available for approximately one year following the presentation [2] Contact Information - Media inquiries can be directed to Ben Petok at bpetok@argenx.com [4] - Investor relations can be contacted through Alexandra Roy at aroy@argenx.com [4]